L&C BIOLTD (A290650) Stock Overview
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
A290650 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeL&C BIO Co.,LTD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩61,700.00 |
| 52 Week High | ₩125,000.00 |
| 52 Week Low | ₩21,500.00 |
| Beta | 1.34 |
| 1 Month Change | -5.95% |
| 3 Month Change | -27.67% |
| 1 Year Change | 161.44% |
| 3 Year Change | 100.32% |
| 5 Year Change | 105.67% |
| Change since IPO | 586.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| A290650 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.4% | -1.0% | 12.5% |
| 1Y | 161.4% | 38.0% | 176.4% |
Return vs Industry: A290650 exceeded the KR Biotechs industry which returned 34.9% over the past year.
Return vs Market: A290650 underperformed the KR Market which returned 173% over the past year.
Price Volatility
| A290650 volatility | |
|---|---|
| A290650 Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in KR Market | 16.2% |
| 10% least volatile stocks in KR Market | 4.7% |
Stable Share Price: A290650's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A290650's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 141 | Chul Lee Whan | www.lncbio.co.kr |
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. The company offers pharmaceuticals, human tissue, medical device, and cosmetics products. L&C Bio Co., Ltd was founded in 2011 and is headquartered in Seongnam-si, South Korea.
L&C BIO Co.,LTD Fundamentals Summary
| A290650 fundamental statistics | |
|---|---|
| Market cap | ₩1.53t |
| Earnings (TTM) | -₩138.28b |
| Revenue (TTM) | ₩85.48b |
Is A290650 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A290650 income statement (TTM) | |
|---|---|
| Revenue | ₩85.48b |
| Cost of Revenue | ₩40.09b |
| Gross Profit | ₩45.39b |
| Other Expenses | ₩183.67b |
| Earnings | -₩138.28b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.57k |
| Gross Margin | 53.10% |
| Net Profit Margin | -161.78% |
| Debt/Equity Ratio | 41.4% |
How did A290650 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/08 09:02 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
L&C BIO Co.,LTD is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chae-eun Lee | Eugene Investment & Securities Co Ltd. |
| Jun Choi | Macquarie Research |
| SungKyu Heo | Shinhan Investment Corp. |